TREATMENT PATTERNS AND CLINICAL OUTCOMES AMONG PATIENTS RECEIVING CDK4/6 INHIBITORS FOR HR+/HER2ADVANCED/METASTATIC BREAST CANCER IN A SINGLE-CENTRE, CANADIAN REAL-WORLD SETTING USING AI-EXTRACTED DATA

被引：0
|
作者：
Moulson, Ruth [1 ]
Feugere, Guillaume [2 ]
Moreira-Lucas, Tracy [2 ]
Dequen, Florence [2 ]
Weiss, Jessica [1 ]
Smith, Janet [3 ]
Brezden-Masley, Christine [3 ]
机构：
[1] Pentavere, Toronto, ON, Canada
[2] Pfizer Canada, Kirkland, PQ, Canada
[3] Mt Sinai Hosp, New York, NY USA
来源：
BREAST | 2023年 / 71卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO107
引用
收藏
页码：S51 / S51
页数：1
相关论文
共 50 条
  • [31] Impact of the introduction of CDK4/6 inhibitors on treatment duration in patients with HR+, HER2-advanced breast cancer: Final analysis of TreatER plus ight, a Canadian prospective, real-world, observational study
    Doyle, Catherine
    Lohmann, Ana Elisa
    Iqbal, Nayyer
    Henning, Jan-Willem
    Kulkarni, Swati
    Califaretti, Nadia
    Hilton, John
    Ferrario, Cristiano
    Bouganim, Nathaniel
    Mates, Mihaela
    Guillemette, Stephanie
    Leite, Ricardo
    Chia, Stephen
    CANCER RESEARCH, 2024, 84 (09)
  • [32] Real-world treatment patterns among advanced HR+/ HER2-breast cancer patients in the post-CDK4/6 inhibitor era: An analysis of administrative claims data.
    Boyle, Tirza Areli Calderon
    Shukla, Soham
    Happ, Lindsey Powers
    Zheng, Shan
    Gorsh, Boris
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [33] Everolimus plus endocrine therapy beyond CDK4/6 inhibitors progression for HR+ /HER2-advanced breast cancer: a real-world evidence cohort
    Sanchez-Bayona, Rodrigo
    de Sa, Alfonso Lopez
    Gilarranz, Yolanda Jerez
    de Torre, Ana Sanchez
    Alva, Manuel
    Echavarria, Isabel
    Moreno, Fernando
    Tolosa, Pablo
    Lopez, Blanca Herrero
    de Luna, Alicia
    Lema, Laura
    Casado, Salvador Gamez
    Madariaga, Ainhoa
    Lopez-Tarruella, Sara
    Manso, Luis
    Bueno-Muino, Coralia
    Garcia-Saenz, Jose A.
    Ciruelos, Eva
    Martin, Miguel
    BREAST CANCER RESEARCH AND TREATMENT, 2024, 206 (03) : 551 - 559
  • [34] Real-world effectiveness of CDK4/6i in first-line treatment of HR+/HER2-advanced/metastatic breast cancer: updated systematic review
    Harbeck, Nadia
    Brufsky, Adam
    Rose, Chloe Grace
    Korytowsky, Beata
    Chen, Connie
    Tantakoun, Krista
    Jazexhi, Endri
    Nguyen, Do Hoang Vien
    Bartlett, Meaghan
    Samjoo, Imtiaz A.
    Pluard, Timothy
    FRONTIERS IN ONCOLOGY, 2025, 15
  • [35] Demographic Characteristics and Treatment Patterns Among Patients Receiving Palbociclib for HR+/HER2-Advanced Breast Cancer: A Nationwide Real-World Experience
    Boer, Katalin
    Rubovszky, Gabor
    Rokszin, Gyorgy
    Abonyi-Toth, Zsolt
    Foldesi, Csenge
    Dank, Magdolna
    ONCOTARGETS AND THERAPY, 2021, 14 : 3971 - 3981
  • [36] Real-world outcomes from use of CDK4/6 inhibitors in the management of advanced/metastatic breast cancer in Asia
    Low, Jia Li
    Lim, Elaine
    Bharwani, Lavina
    Wong, Andrea
    Wong, Karmen
    Ow, Samuel
    Lim, Siew Eng
    Lee, Matilda
    Choo, Joan
    Lim, Joline
    Chan, Gloria
    Walsh, Robert John
    Muthu, Vaishnavi
    Ngoi, Natalie
    Chong, Wanqin
    Tan, Sing Huang
    Lee, Soo Chin
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [37] Predicting CDK4/6 inhibitors outcomes in pts with HR+/HER2-metastatic breast cancer: A machine learning approach
    Moiso, Enrico
    Ferraro, Emanuela
    Cabel, Luc
    Safonov, Anton
    Ahmed, Mehnaj
    An, Julia Ah-Reum
    Jhaveri, Komal L.
    Norton, Larry
    Robson, Mark E.
    Modi, Shanu
    Chandarlapaty, Sarat
    Razavi, Pedram
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [38] Real-world clinico-genomic data reveal differences in genomic landscape associated with CDK4/6 inhibitors in HR+/HER2-breast cancer
    Chaudhary, Nayan
    Mecalfe, Ciara
    Hafner, Marc
    CANCER RESEARCH, 2023, 83 (05)
  • [39] Treatment patterns and outcomes associated with sequential and non-sequential use of CDK4 & 6 inhibitors in patients with HR+, HER2− MBC in the real world
    Megan Kruse
    Emily Nash Smyth
    Lee Bowman
    Santosh Gautam
    Claudia M. Guimaraes
    Alnecia R. Nisbett
    Maxine D. Fisher
    Zhanglin Lin Cui
    Kristin M. Sheffield
    Kevin Kalinsky
    Breast Cancer Research and Treatment, 2023, 201 : 105 - 115
  • [40] Treatment patterns and outcomes associated with sequential and non-sequential use of CDK4 & 6 inhibitors in patients with HR+, HER2-MBC in the real world
    Kruse, Megan
    Smyth, Emily Nash
    Bowman, Lee
    Gautam, Santosh
    Guimaraes, Claudia M.
    Nisbett, Alnecia R.
    Fisher, Maxine D.
    Cui, Zhanglin Lin
    Sheffield, Kristin M.
    Kalinsky, Kevin
    BREAST CANCER RESEARCH AND TREATMENT, 2023, 201 (01) : 105 - 115
12345